CN103622027B - 一种降血糖保健食品组合物 - Google Patents
一种降血糖保健食品组合物 Download PDFInfo
- Publication number
- CN103622027B CN103622027B CN201310697321.7A CN201310697321A CN103622027B CN 103622027 B CN103622027 B CN 103622027B CN 201310697321 A CN201310697321 A CN 201310697321A CN 103622027 B CN103622027 B CN 103622027B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- grams
- food composition
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 235000013305 food Nutrition 0.000 title claims abstract description 22
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 18
- 208000013016 Hypoglycemia Diseases 0.000 title claims abstract description 16
- 239000003292 glue Substances 0.000 claims abstract description 13
- 235000017276 Salvia Nutrition 0.000 claims abstract description 12
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 6
- 241001072909 Salvia Species 0.000 claims abstract 3
- 239000008280 blood Substances 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 9
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 5
- 206010012655 Diabetic complications Diseases 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 4
- 230000007102 metabolic function Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000003750 conditioning effect Effects 0.000 abstract description 2
- 230000035622 drinking Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 240000007164 Salvia officinalis Species 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000008103 glucose Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 5
- 235000005412 red sage Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241001092040 Crataegus Species 0.000 description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930189092 Notoginsenoside Natural products 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000864 hyperglycemic agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种降血糖保健食品组合物,按质量份数比由下述组分组成:蜂胶粉10~12份、三七提取物5~7份、丹参提取物9~11份、黄精提取物10~12份、灵芝提取物2~4份、山楂提取物7~9份;还包括药学上可以接受的适量辅料。通过药食同源提取物及中医药提取物进行复方组配,科学配伍,协同增效,有效降低血糖;同时通过该保健食品组合物的调理,使人体机能达到平衡,益气养阴,提高人体代谢机能和免疫力,降低糖尿病并发症的发生。
Description
背景技术
糖尿病(diabetesmellitus,DM)是一种慢性常见内分泌代谢性疾病,多伴有并发症,且发病率有逐年增高的趋势,WHO最近发表报告指出,糖尿病已成为威胁人类生命的"三大杀手"之一。当今糖尿病的治疗方案,世界各国都十分推崇饮食疗法,大力强调饮食疗法的重要性,强调在饮食疗法基础上配合运动治疗、药物治疗等的整体治疗方案。由于糖尿病的终身不可愈性以及耐药性、抗药性及药品的副作用等原因,这类人群对降糖保健食品的需求量非常大。但是现有同类保健食品的降血糖效果还有待提高。同时现有中药降糖产品主要是通过调节胰岛素和糖代谢为主,来达到稳定血糖的目的。对于因糖代谢紊乱而产生的并发症无改善作用。
发明内容
为了解决上述弊端,本发明所要解决的技术问题是,提供一种能够有效降低人体血糖的保健食品组合物。为了解决上述技术问题,本发明采用的技术方案是,一种降血糖保健食品组合物,所述组合物按质量份数比由下述组分组成:蜂胶粉10~12份、三七提取物5~7份、丹参提取物9~11份、黄精提取物10~12份、灵芝提取物2~4份、山楂提取物7~9份;还包括药学上可以接受的适量辅料。
上述配方中各组分均为可市场购得的原材料,经检验合格后,过60目筛,按配比称量,按一般方法充分混合。加入药学上可以接受的适量辅料如淀粉制成颗粒剂、胶囊剂、片剂等。
优选地,所述组合物按质量份数比由下述组分组成:蜂胶粉11份、三七提取物6份、丹参提取物10份、黄精提取物11份、灵芝提取物3份、山楂提取物8份。
上述技术方案的药理机制在于:
三七提取物:实验证明,三七皂苷c1能降低四氧嘧啶糖尿病小鼠血糖,作用呈量效关系,并能拮抗胰高血糖素的降血糖作用;同时三七粉对于糖尿病并发症心脏病具有较好的治疗效果;还具有治疗糖尿病肢端坏疽的功效。需要注意的是,三七对人体物质代谢的影响是多方面的,三七皂苷对血糖的影响取决于动物的状态及机体血糖水平,pns有协同胰高血糖素的升血糖作用。
丹参提取物:以往丹参主要用于心脑血管疾病的治疗上。但是糖尿病患者,特别是中老年糖尿病患者最突出、最主要的病理改变为全身性弥散性血管的病变,表现为微循环障碍,微血管瘤形成和微血管基底膜增厚。考虑到丹参能拮抗血管紧张素,有效地降低血液的粘度、抑制血小板聚集,提高纤维蛋白酶溶解性,还能清除氧自由基,并能抑制内源性胆固醇的合成,降低血液中甘油三酯和胆固醇的含量。药理学研究和临床观察表明:丹参具有降低血糖、防治糖尿病并发症、调节血脂、改善微循环的作用,常服可预防和治疗糖尿病以及糖尿病导致的酮症酸中毒、低血糖,以及大血管、微血管和周围神经病变等严重并发症,降低因并发症导致的致死、致残率,减少医疗费用支出。例如,对于糖尿病肾病患者,丹参具有减少尿白蛋白、保护肾功能、延缓病情发展的作用;丹参还能明显改善糖尿病患者由于血液粘稠度过高、微循环障碍导致的肢体麻木、疼痛等临床症状,疗效确切而且安全,作用平稳而持久。
灵芝提取物:就中医辩证看,由于本品入五脏肾补益全身五脏之气,所以无论心、肺、肝、脾、肾脏虚弱,均可服之。灵芝所治病种涉及呼吸、循环、消化、神经、内分泌及运动等各个***;涵盖内、外、妇、儿、五官各科疾病。其根本原因,就在于灵芝扶正固本,增强免疫功能,提高机体抵抗力的巨大作用。在本组合物中加入灵芝提取物不是单对某种疾病而起治疗作用,也不是只对某一方面营养素的不足进行补充和强化,而是在整体上双向调节人体机能平衡,调动机体内部活力,调节人体新陈代谢机能,提高自身免疫能力,促使全部的内脏或器官机能正常化。
山楂提取物:中医认为,山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。具有显著的扩张血管及降压作用,有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能。能舒张血管、加强和调节心肌,增大心室和心运动振幅及冠状动脉血流量,降低血清胆固醇和降低血压;此外,山楂对心脏活动功能障碍、血管性神经官能症、颤动性心律失常等症也有辅助治疗作用;山植还含有槲皮苷,它有扩张血管、促进气管纤毛运动、排痰平喘之功能,故山楂是防治心血管病的理想保健食品和有较好疗效的食品,近来应用于高血压、高血脂、冠心病等的防治,均有较好效果。
黄精提取物:黄精以根茎入药,其降血糖作用比较确定。具有补气养阴,健脾,润肺,益肾功能。用于治疗脾胃虚弱,体倦乏力,口干食少,肺虚燥咳,精血不足,内热消渴等症。
按照中医学理论可将糖尿病的病因病机及演变规律总结为:阴虚为糖尿病发生的实质,气虚为糖尿病不愈之症结,血痕是糖尿病合并症的关键,阴阳两虚是糖尿病发病的趋势,治疗上以益气养阴为主,兼以活血清热。
本发明的有益效果在于,通过药食同源提取物及中医药提取物进行复方组配,科学配伍,协同增效,有效降低血糖;同时通过该保健食品组合物的调理,使人体机能达到平衡,益气养阴,提高人体代谢机能和免疫力,降低糖尿病并发症的发生。
下面将结合附图和具体实施方式对本发明做进一步说明。
附图说明
附图为本发明降血糖保健食品组合物胶囊剂制备实施例的工艺流程框图。
具体实施方式
实施例1:参见附图,反映本发明的一种具体制备方式,所述降血糖保健食品组合物的配方是:蜂胶粉55克、三七提取物30克、丹参提取物50克、黄精提取物55克、灵芝提取物15克、山楂提取物40克、淀粉55克。以上原辅料分别经检验合格后,分别过60目筛,按配方称量,按一般方法充分混合5秒即得混合粉。混合粉经填充制成胶囊剂,经抛光、筛选、按照0.3g/粒,120粒/瓶进行内、外包装,检验入库。本实施例可制得成品1000粒。
实施例2:与实施例1的不同之处在于,所述降血糖保健食品组合物的配方是:蜂胶粉50克、三七提取物25克、丹参提取物45克、黄精提取物50克、灵芝提取物10克、山楂提取物35克、淀粉50克。其余均相同。
实施例3:与实施例1的不同之处在于,所述降血糖保健食品组合物的配方是:蜂胶粉60克、三七提取物35克、丹参提取物55克、黄精提取物60克、灵芝提取物20克、山楂提取物45克、淀粉60克。其余均相同。
实施例4:与实施例1的不同之处在于,所述降血糖保健食品组合物的配方是:蜂胶粉55克、三七提取物35克、丹参提取物45克、黄精提取物55克、灵芝提取物10克、山楂提取物40克、淀粉55克。其余均相同。
实施例5:与实施例1的不同之处在于,所述降血糖保健食品组合物的配方是:蜂胶粉50克、三七提取物30克、丹参提取物55克、黄精提取物60克、灵芝提取物15克、山楂提取物45克、淀粉60克。其余均相同。
实施例6:与实施例1的不同之处在于,所述降血糖保健食品组合物的配方是:蜂胶粉60克、三七提取物25克、丹参提取物50克、黄精提取物50克、灵芝提取物20克、山楂提取物35克、淀粉50克。其余均相同。
临床观察报告
临床资料:2013年3月到5月,共选取80例糖尿病患者作为治疗对象,其中男性40人,女性40人,平均年龄为55.3岁,随机分成A、B两组,每组男性20人,女性20人。
治疗方法:A组:服用市售某品牌降血糖保健品——蜂胶软胶囊,2次/日,每次3粒,作为参照组。其主要成分为蜂胶、聚乙二醇400、明胶、甘油,每100g含总黄酮4.2g。B组:服用按本发明方法制得的降血糖保健食品组合物胶囊,2次/日,每次四粒。所有患者服用4周后停止服用,再观察4周。
疗效评定标准:在服用药物1天前,服用药物4周后和停服药物4周后,对每组分别检测空腹血糖指标;有效~血糖指标下降;显著~血糖指标控制在正常值范围。所有指标用均数±标准差表示,应用t检验的统计方法对结果进行分析,P<0.05认为具有显著意义。治疗结果见附表。
(表1)两组患者服用药物4周后疗效结果比较
由表1可以看出,A组和B组服用药物4周及停服4周后血糖指标比服用前都有明显下降,服用药物4周后A组和B组有效率均为100%,显著率B组要高于A组。停服4周后,A组有效率略低于B组,显著率B组还维持有20%,A组为0%。
(表2)两组患者服用药物前后空腹血糖的比较(mmol/L)
组别 | 服用前 | 服用后4周 | 停服4周后 |
A组 | 10.5±1.1 | 7.6±1.2 | 8.7±1.1 |
B组 | 10.3±0.9 | 6.8±0.9 | 7.5±1.0 |
由表2可以看出,A组和B组服用药物4周及停服4周后血糖指标比服用前都有明显下降,但可以明显看出,B组4周后的血糖指标明显低于服用蜂胶软胶囊的A组,停药4周后,B组患者的血糖指标浮动不大,A组患者血糖指标上升浮动较大。所以本发明制得的降血糖保健食品组合物具有降血糖效果的明显优势。
本发明描述的上述实现方式仅是为了清楚的说明本发明的技术方案,而不能理解为对本发明作出任何限制。在本说明书的指导下,本领域技术人员可以在发明内容部分所提出的配比范围内任意调整,以得到各种具体实施例而实现本发明。本发明在本技术领域具有公知的多种替代或者变形,在不脱离本发明实质意义的前提下,均落入本发明的保护范围。
Claims (2)
1.一种降血糖保健食品组合物,其特征在于,所述组合物按质量份数比由下述组分组成:蜂胶粉10~12份、三七提取物5~7份、丹参提取物9~11份、黄精提取物10~12份、灵芝提取物2~4份、山楂提取物7~9份,还包括药学上可以接受的适量辅料。
2.如权利要求1所述的一种降血糖保健食品组合物,其特征在于,所述组合物按质量份数比由下述组分组成:蜂胶粉11份、三七提取物6份、丹参提取物10份、黄精提取物11份、灵芝提取物3份、山楂提取物8份、药学上可以接受的适量辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310697321.7A CN103622027B (zh) | 2013-12-18 | 2013-12-18 | 一种降血糖保健食品组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310697321.7A CN103622027B (zh) | 2013-12-18 | 2013-12-18 | 一种降血糖保健食品组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103622027A CN103622027A (zh) | 2014-03-12 |
CN103622027B true CN103622027B (zh) | 2016-01-27 |
Family
ID=50203758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310697321.7A Active CN103622027B (zh) | 2013-12-18 | 2013-12-18 | 一种降血糖保健食品组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103622027B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105475733A (zh) * | 2014-09-19 | 2016-04-13 | 深圳华大基因研究院 | 一种保健食品及其制备方法 |
CN104287041A (zh) * | 2014-10-29 | 2015-01-21 | 陈林 | 一种黄精蜂胶保健饮料 |
CN104523829B (zh) * | 2014-12-18 | 2018-06-01 | 威海百合生物技术股份有限公司 | 一种蜂胶丹参保健食品 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596736A (zh) * | 2004-08-31 | 2005-03-23 | 陈季平 | 三七蜂胶保健食品 |
CN101371902A (zh) * | 2008-08-22 | 2009-02-25 | 浙江省医学科学院 | 天然活性糖元保降血糖、降血脂的作用 |
CN101428117A (zh) * | 2008-12-04 | 2009-05-13 | 雷双富 | 通脉降脂药物及其制备方法 |
CN102670978A (zh) * | 2012-06-06 | 2012-09-19 | 张旺凡 | 一种黄精复方颗粒剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100829057B1 (ko) * | 2006-08-25 | 2008-05-16 | 김희성 | 프로폴리스와 한약재를 배합한 혈당저하 식품조성물 및 그제조방법 |
-
2013
- 2013-12-18 CN CN201310697321.7A patent/CN103622027B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596736A (zh) * | 2004-08-31 | 2005-03-23 | 陈季平 | 三七蜂胶保健食品 |
CN101371902A (zh) * | 2008-08-22 | 2009-02-25 | 浙江省医学科学院 | 天然活性糖元保降血糖、降血脂的作用 |
CN101428117A (zh) * | 2008-12-04 | 2009-05-13 | 雷双富 | 通脉降脂药物及其制备方法 |
CN102670978A (zh) * | 2012-06-06 | 2012-09-19 | 张旺凡 | 一种黄精复方颗粒剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103622027A (zh) | 2014-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020172523A (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び/又は刺激におけるその使用 | |
CN102600212B (zh) | 一种增强免疫力、辅助***的医药保健品 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN102784162A (zh) | 一种食用菌类复合多糖养生保健治疗剂 | |
CN102526478A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN103169793B (zh) | 一种治疗三高症的药物 | |
CN103622027B (zh) | 一种降血糖保健食品组合物 | |
CN107468747A (zh) | 一种有利于抗癌、防癌的人参组合物及其制备方法 | |
CN101999663A (zh) | 中药组合物在制备缓解体力疲劳保健食品及药品中的应用 | |
CN103405577A (zh) | 一种增强免疫力、缓解疲劳的药用组合物 | |
CN101744874B (zh) | 一种抗肿瘤复方蜂乳液及其制备方法 | |
CN103550281A (zh) | 一种预防和治疗糖尿病及其并发症的药物组合物及其制剂 | |
CN104225295B (zh) | 用于改善睡眠的组合物及其制备方法和应用 | |
CN102784163A (zh) | 一种食用菌类复合多糖养生保健治疗配方及其制备方法 | |
CN103239470B (zh) | 一种含鸡腿蘑多糖和香菇多糖的双菇多糖组合物及其制法和用途 | |
CN102228620B (zh) | 一种补铁补血的中药复方制剂及其制备方法 | |
US10383904B2 (en) | Composition for improving health and quality of life of women containing ginseng berry extract | |
CN101112236A (zh) | 一种具有耐缺氧功能的保健品 | |
CN106511915A (zh) | 一种复方中药组合物在抑制皮肤黑色素瘤肺转移药物中的应用 | |
CN102552677B (zh) | 黄地安消胶囊及其制备方法 | |
CN106177712A (zh) | 一种治疗心脑血管疾病的华蒜豆及其制备方法 | |
CN106729304B (zh) | 一种减轻禁食或节食副反应的中药及其制备方法 | |
CN105998196A (zh) | 一种含绞股蓝的降血糖保健药物组合物 | |
CN100391484C (zh) | 治疗心脑血管疾病的药物 | |
CN101537079B (zh) | 改善睡眠、延缓衰老的药物组合物或保健品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |